FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048376209> ?p ?o ?g. }

• W3048376209 endingPage "e0237693" @default.
• W3048376209 startingPage "e0237693" @default.
• W3048376209 abstract "Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80–1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83–1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75–1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57–1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier: NCT04347993" @default.
• W3048376209 created "2020-08-18" @default.
• W3048376209 creator A5004548544 @default.
• W3048376209 creator A5007239934 @default.
• W3048376209 creator A5007837091 @default.
• W3048376209 creator A5011797345 @default.
• W3048376209 creator A5016346045 @default.
• W3048376209 creator A5017772744 @default.
• W3048376209 creator A5019383380 @default.
• W3048376209 creator A5019400356 @default.
• W3048376209 creator A5021959578 @default.
• W3048376209 creator A5024177112 @default.
• W3048376209 creator A5025036628 @default.
• W3048376209 creator A5033513950 @default.
• W3048376209 creator A5036078876 @default.
• W3048376209 creator A5046016119 @default.
• W3048376209 creator A5046306389 @default.
• W3048376209 creator A5048343893 @default.
• W3048376209 creator A5051483089 @default.
• W3048376209 creator A5059160203 @default.
• W3048376209 creator A5060006369 @default.
• W3048376209 creator A5063691133 @default.
• W3048376209 creator A5066691278 @default.
• W3048376209 creator A5070492766 @default.
• W3048376209 creator A5072154757 @default.
• W3048376209 creator A5073571977 @default.
• W3048376209 creator A5074715840 @default.
• W3048376209 creator A5074860192 @default.
• W3048376209 creator A5077690677 @default.
• W3048376209 creator A5078450617 @default.
• W3048376209 creator A5086123685 @default.
• W3048376209 creator A5086344645 @default.
• W3048376209 creator A5087206210 @default.
• W3048376209 creator A5089882481 @default.
• W3048376209 date "2020-08-13" @default.
• W3048376209 modified "2023-10-14" @default.
• W3048376209 title "Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study" @default.
• W3048376209 cites W1560478899 @default.
• W3048376209 cites W2036193982 @default.
• W3048376209 cites W2093274439 @default.
• W3048376209 cites W2095807050 @default.
• W3048376209 cites W2100967823 @default.
• W3048376209 cites W2560688864 @default.
• W3048376209 cites W2610356532 @default.
• W3048376209 cites W2810037075 @default.
• W3048376209 cites W2944434778 @default.
• W3048376209 cites W3001118548 @default.
• W3048376209 cites W3003465021 @default.
• W3048376209 cites W3004709581 @default.
• W3048376209 cites W3005212621 @default.
• W3048376209 cites W3007940623 @default.
• W3048376209 cites W3008443627 @default.
• W3048376209 cites W3008827533 @default.
• W3048376209 cites W3009577418 @default.
• W3048376209 cites W3010673910 @default.
• W3048376209 cites W3010930696 @default.
• W3048376209 cites W3010992334 @default.
• W3048376209 cites W3014333693 @default.
• W3048376209 cites W3016154368 @default.
• W3048376209 cites W3022970339 @default.
• W3048376209 cites W3023082818 @default.
• W3048376209 cites W3023346879 @default.
• W3048376209 cites W3036398841 @default.
• W3048376209 cites W3041464116 @default.
• W3048376209 cites W3044118599 @default.
• W3048376209 cites W4239728164 @default.
• W3048376209 doi "https://doi.org/10.1371/journal.pone.0237693" @default.
• W3048376209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7425928" @default.
• W3048376209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32790733" @default.
• W3048376209 hasPublicationYear "2020" @default.
• W3048376209 type Work @default.
• W3048376209 sameAs 3048376209 @default.
• W3048376209 citedByCount "98" @default.
• W3048376209 countsByYear W30483762092020 @default.
• W3048376209 countsByYear W30483762092021 @default.
• W3048376209 countsByYear W30483762092022 @default.
• W3048376209 countsByYear W30483762092023 @default.
• W3048376209 crossrefType "journal-article" @default.
• W3048376209 hasAuthorship W3048376209A5004548544 @default.
• W3048376209 hasAuthorship W3048376209A5007239934 @default.
• W3048376209 hasAuthorship W3048376209A5007837091 @default.
• W3048376209 hasAuthorship W3048376209A5011797345 @default.
• W3048376209 hasAuthorship W3048376209A5016346045 @default.
• W3048376209 hasAuthorship W3048376209A5017772744 @default.
• W3048376209 hasAuthorship W3048376209A5019383380 @default.
• W3048376209 hasAuthorship W3048376209A5019400356 @default.
• W3048376209 hasAuthorship W3048376209A5021959578 @default.
• W3048376209 hasAuthorship W3048376209A5024177112 @default.
• W3048376209 hasAuthorship W3048376209A5025036628 @default.
• W3048376209 hasAuthorship W3048376209A5033513950 @default.
• W3048376209 hasAuthorship W3048376209A5036078876 @default.
• W3048376209 hasAuthorship W3048376209A5046016119 @default.
• W3048376209 hasAuthorship W3048376209A5046306389 @default.
• W3048376209 hasAuthorship W3048376209A5048343893 @default.
• W3048376209 hasAuthorship W3048376209A5051483089 @default.
• W3048376209 hasAuthorship W3048376209A5059160203 @default.
• W3048376209 hasAuthorship W3048376209A5060006369 @default.
• W3048376209 hasAuthorship W3048376209A5063691133 @default.

• next